Nitration and Increased α‐Synuclein Expression Associated With Dopaminergic Neurodegeneration In Equine Pituitary Pars Intermedia Dysfunction
Identifieur interne : 002364 ( Istex/Curation ); précédent : 002363; suivant : 002365Nitration and Increased α‐Synuclein Expression Associated With Dopaminergic Neurodegeneration In Equine Pituitary Pars Intermedia Dysfunction
Auteurs : D. Mcfarlane ; N. Dybdal [États-Unis] ; M. T. Donaldson [États-Unis] ; L. Miller [Canada] ; A. E. CribbSource :
- Journal of Neuroendocrinology [ 0953-8194 ] ; 2005-02.
English descriptors
- KwdEn :
Abstract
Equine pituitary pars intermedia dysfunction (PPID) is a spontaneously occurring progressive disease affecting aged horses and ponies. The pathogenesis of PPID is poorly understood, but the available evidence supports a loss of dopaminergic inhibition of the melanotropes of the pars intermedia. Horses with PPID have increased plasma concentrations of pars intermedia pro‐opiomelanocortin‐derived peptides that decrease in response to dopamine or dopamine agonist administration. Dopamine and dopamine metabolite concentrations are decreased in the pars intermedia of affected horses compared to age‐matched control horses. Horses with disease that are treated with the dopamine agonist pergolide show improvement in clinical signs and normalisation of diagnostic test results. In the present study, immunohistochemical evaluation of pituitary and hypothalamic tissue demonstrated reduced tyrosine hydroxylase immunoreactivity in affected horses compared to age‐matched and young controls, supporting the role of dopaminergic neurodegeneration in PPID. In addition, immunohistochemical evaluation revealed an increase in the oxidative stress marker, 3‐nitrotyrosine and in nerve terminal protein, α‐synuclein that colocalised in the pars intermedia of horses with disease. These findings suggest a role for nitration of overexpressed α‐synuclein in the pathogenesis of neurodegeneration in PPID.
Url:
DOI: 10.1111/j.1365-2826.2005.01277.x
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002364
Links to Exploration step
ISTEX:D3F3EDC68DBECBD032A60D17E29B97676CB4A89ECuration
No country items
D. Mcfarlane<affiliation><mods:affiliation>Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences</mods:affiliation><wicri:noCountry code="subField">Sciences</wicri:noCountry></affiliation><affiliation><mods:affiliation>Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences</mods:affiliation><wicri:noCountry code="subField">Sciences</wicri:noCountry></affiliation>Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nitration and Increased α‐Synuclein Expression Associated With Dopaminergic Neurodegeneration In Equine Pituitary Pars Intermedia Dysfunction</title><author><name sortKey="Mcfarlane, D" sort="Mcfarlane, D" uniqKey="Mcfarlane D" first="D." last="Mcfarlane">D. Mcfarlane</name><affiliation><mods:affiliation>Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences</mods:affiliation><wicri:noCountry code="subField">Sciences</wicri:noCountry></affiliation></author><author><name sortKey="Dybdal, N" sort="Dybdal, N" uniqKey="Dybdal N" first="N." last="Dybdal">N. Dybdal</name><affiliation wicri:level="1"><mods:affiliation>Genentech, South San Francisco, California, USA.</mods:affiliation><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea></affiliation></author><author><name sortKey="Donaldson, M T" sort="Donaldson, M T" uniqKey="Donaldson M" first="M. T." last="Donaldson">M. T. Donaldson</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA, USA.</mods:affiliation><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA</wicri:regionArea></affiliation></author><author><name sortKey="Miller, L" sort="Miller, L" uniqKey="Miller L" first="L." last="Miller">L. Miller</name><affiliation wicri:level="1"><mods:affiliation>Department of Pathology and Microbiology, Atlantic Veterinary College, Charlottetown, PE, Canada.</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology and Microbiology, Atlantic Veterinary College, Charlottetown, PE</wicri:regionArea></affiliation></author><author><name sortKey="Cribb, A E" sort="Cribb, A E" uniqKey="Cribb A" first="A. E." last="Cribb">A. E. Cribb</name><affiliation><mods:affiliation>Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences</mods:affiliation><wicri:noCountry code="subField">Sciences</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D3F3EDC68DBECBD032A60D17E29B97676CB4A89E</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1111/j.1365-2826.2005.01277.x</idno><idno type="url">https://api-v5.istex.fr/document/D3F3EDC68DBECBD032A60D17E29B97676CB4A89E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002364</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002364</idno><idno type="wicri:Area/Istex/Curation">002364</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Nitration and Increased α‐Synuclein Expression Associated With Dopaminergic Neurodegeneration In Equine Pituitary Pars Intermedia Dysfunction</title><author><name sortKey="Mcfarlane, D" sort="Mcfarlane, D" uniqKey="Mcfarlane D" first="D." last="Mcfarlane">D. Mcfarlane</name><affiliation><mods:affiliation>Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences</mods:affiliation><wicri:noCountry code="subField">Sciences</wicri:noCountry></affiliation></author><author><name sortKey="Dybdal, N" sort="Dybdal, N" uniqKey="Dybdal N" first="N." last="Dybdal">N. Dybdal</name><affiliation wicri:level="1"><mods:affiliation>Genentech, South San Francisco, California, USA.</mods:affiliation><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Genentech, South San Francisco, California</wicri:regionArea></affiliation></author><author><name sortKey="Donaldson, M T" sort="Donaldson, M T" uniqKey="Donaldson M" first="M. T." last="Donaldson">M. T. Donaldson</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA, USA.</mods:affiliation><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA</wicri:regionArea></affiliation></author><author><name sortKey="Miller, L" sort="Miller, L" uniqKey="Miller L" first="L." last="Miller">L. Miller</name><affiliation wicri:level="1"><mods:affiliation>Department of Pathology and Microbiology, Atlantic Veterinary College, Charlottetown, PE, Canada.</mods:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology and Microbiology, Atlantic Veterinary College, Charlottetown, PE</wicri:regionArea></affiliation></author><author><name sortKey="Cribb, A E" sort="Cribb, A E" uniqKey="Cribb A" first="A. E." last="Cribb">A. E. Cribb</name><affiliation><mods:affiliation>Laboratory of Comparative Pharmacogenetics, Department of Biomedical Sciences</mods:affiliation><wicri:noCountry code="subField">Sciences</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroendocrinology</title><idno type="ISSN">0953-8194</idno><idno type="eISSN">1365-2826</idno><imprint><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2005-02">2005-02</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="73">73</biblScope><biblScope unit="page" to="80">80</biblScope></imprint><idno type="ISSN">0953-8194</idno></series><idno type="istex">D3F3EDC68DBECBD032A60D17E29B97676CB4A89E</idno><idno type="DOI">10.1111/j.1365-2826.2005.01277.x</idno><idno type="ArticleID">JNE1277</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0953-8194</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>3‐nitrotyrosine</term><term>alpha synuclein</term><term>equine Cushing's disease</term><term>equine pituitary pars intermedia dysfunction</term><term>oxidative stress</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Equine pituitary pars intermedia dysfunction (PPID) is a spontaneously occurring progressive disease affecting aged horses and ponies. The pathogenesis of PPID is poorly understood, but the available evidence supports a loss of dopaminergic inhibition of the melanotropes of the pars intermedia. Horses with PPID have increased plasma concentrations of pars intermedia pro‐opiomelanocortin‐derived peptides that decrease in response to dopamine or dopamine agonist administration. Dopamine and dopamine metabolite concentrations are decreased in the pars intermedia of affected horses compared to age‐matched control horses. Horses with disease that are treated with the dopamine agonist pergolide show improvement in clinical signs and normalisation of diagnostic test results. In the present study, immunohistochemical evaluation of pituitary and hypothalamic tissue demonstrated reduced tyrosine hydroxylase immunoreactivity in affected horses compared to age‐matched and young controls, supporting the role of dopaminergic neurodegeneration in PPID. In addition, immunohistochemical evaluation revealed an increase in the oxidative stress marker, 3‐nitrotyrosine and in nerve terminal protein, α‐synuclein that colocalised in the pars intermedia of horses with disease. These findings suggest a role for nitration of overexpressed α‐synuclein in the pathogenesis of neurodegeneration in PPID.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002364 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002364 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:D3F3EDC68DBECBD032A60D17E29B97676CB4A89E
|texte= Nitration and Increased α‐Synuclein Expression Associated With Dopaminergic Neurodegeneration In Equine Pituitary Pars Intermedia Dysfunction
}}
| This area was generated with Dilib version V0.6.29. |  |